SRBT — Shanrong Biotechnology Income Statement
0.000.00%
HealthcareHighly SpeculativeSmall Cap
- $122.32m
- $124.20m
- $1.32m
Annual income statement for Shanrong Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2007 July 31st | 2008 July 31st | 2009 December 31st | |
|---|---|---|---|
| Period Length: | 8 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 1.32 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 0.053 | 0.04 | 6.13 |
| Operating Profit | -0.053 | -0.04 | -4.81 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -0.053 | -0.04 | -5.08 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -0.053 | -0.04 | -5.08 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.053 | -0.04 | -5.08 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Dilution Adjustment | |||
| Diluted Net Income | -0.053 | -0.04 | -5.08 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.156 | -0.07 | -15.7 |
| Dividends per Share |